Communication of Harms

This page lists 103 references in the Main Healthy Skepticism Library relevant to communication about the harms of therapies.

Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.


HSL6124
Ferner RE, Aronson JK.
Drugs: Communicating information about drug safety
BMJ 2006 Jul 15;333(7559):143-145
http://bmj.bmjjournals.com/cgi/content/short/333/7559/143?etoc

HSL5956
Cassels A.
Women’s health and the Flat Earth Society
Common Ground 2006 Jul 1
http://www.commonground.ca/iss/0607180/cg180_cassels.shtml

HSL6648
Fonacier L, Charlesworth EN, Spergel JM, Leung DY.
The black box warning for topical calcineurin inhibitors: looking outside the box.
Ann Allergy Asthma Immunol 2006 Jul 01;97(1):117-20

HSL5808
Hagan P.
Four in five asthma deaths may be due to long acting beta agonists.
BMJ 2006 Jun 24;332(7556):1467
http://bmj.bmjjournals.com/cgi/content/extract/332/7556/1467-a

HSL6323
Lee SK.
Re-examining our approach to the approval and use of new drugs.
CMAJ 2006 Jun 20;174(13):1855
http://www.cmaj.ca/cgi/content/full/174/13/1855

HSL5769
Mhlongo SW, Mbokazi AJ.
Ethnic differences in risks of adverse reactions: Biomedical approach is insufficient to explain ethnic differences.
BMJ 2006 Jun 10;332(7554):1393
http://bmj.bmjjournals.com/cgi/content/short/332/7554/1393-a?etoc

HSL5770
Couper MR, Pal SN, Rago L, Sawyer J.
WHO perspective on preventing avoidable harm from medicines.
BMJ 2006 Jun 10;332(7554):1393-4
http://bmj.bmjjournals.com/cgi/content/short/332/7554/1393-b?etoc

HSL5732
Avorn J, Shrank W.
Highlights and a hidden hazard--the FDA's new labeling regulations.
N Engl J Med 2006 Jun 8;354(23):2409-11
http://content.nejm.org/cgi/content/extract/354/23/2409

HSL5992
Dobson R.
Diethylstilbestrol increases risk of breast cancer death
BMJ 2006 Jun 8;333(7558):64
http://bmj.bmjjournals.com/cgi/content/short/333/7558/64-d?etoc

HSL5963
Dieppe P.
Complicity theory: an explanation for the 'coxib problem'?
J R Soc Med 2006 Jun 01;99(6):273-4
http://www.jrsm.org/cgi/content/full/99/6/273

HSL6614
Westerlund LT, Bjork HT.
Pharmaceutical care in community pharmacies: practice and research in Sweden.
Ann Pharmacother 2006 Jun 01;40(6):1162-9
http://www.theannals.com/cgi/content/full/40/6/1162

HSL5742
Wadman M.
How does a painkiller harm the heart?
Nature 2006 May 18;441(7091):262
http://www.nature.com/news/2006/060515/full/441264a.html

HSL5577
Hu A, Chow CM, Dao D, Errett L, Keith M.
Factors influencing patient knowledge of warfarin therapy after mechanical heart valve replacement.
J Cardiovasc Nurs 2006 May-Jun;21(3):169-75
http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00005082-200605000-00003

HSL5594
Rosenthal E.
British rethinking test rules after drug trial nearly kills 6.
NY Times (Print) 2006 Apr 8;A1

HSL5962
Kline AD.
On complicity theory.
Sci Eng Ethics 2006 Apr 01;12(2):257-64

HSL6227
Baldwin HJ, Droege M, Daniel KL.
A message from the Vioxx case.
Am J Health Syst Pharm 2006 Mar 15;63(6):503
http://www.ajhp.org/cgi/content/full/63/6/503

HSL5335
Burton TM.
Amid alarm bells, a blood substitute keeps pumping; ten in trial have heart attacks, but data aren't published; FDA allows a new study; doctors' pleas are ignored.
Wall St J (East Ed) 2006 Feb 22;A1

HSL5360
Sandstrom H.
[More than 1 out of 100 will have myocardial infarction and stroke because of enalapril--effect of drug package inserts?]
Lakartidningen 2006 Feb 22-28;103(8):564,

HSL5425
Lasser KE, Seger DL, Yu DT, Karson AS, Fiskio JM, Seger AC, Shah NR, Gandhi TK, Rothschild JM, Bates DW.
Adherence to black box warnings for prescription medications in outpatients.
Arch Intern Med 2006 Feb 13;166(3):338-44
http://archinte.ama-assn.org/cgi/content/full/166/3/338

HSL6208
Chur-Hansen A, Zion D.
'Let's fix the chemical imbalance first, and then we can work on the problems second': an exploration of ethical implications of prescribing an SSRI for 'depression'.
Monash Bioeth Rev 2006 Jan 01;25(1):15-30

HSL5239
Murphy S, Roberts R.
'Black box' 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
J Allergy Clin Immunol 2006 Jan;117(1):34-9
http://linkinghub.elsevier.com/retrieve/pii/S0091-6749(05)02325-0

HSL5241
Szefler SJ, Whelan GJ, Leung DY.
'Black box' warning: wake-up call or overreaction?
J Allergy Clin Immunol 2006 Jan;117(1):26-9
http://linkinghub.elsevier.com/retrieve/pii/S0091-6749(05)02509-1

HSL5308
Prescription for trouble: common drugs, hidden dangers Tens of people are at risk.
Consum Rep 2006 Jan;71(1):34-9

HSL5319
Warning on unapproved alternative hormone therapies.
FDA Consum 2006 Jan-Feb;40(1):2
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=4686&uid=16528817&db=PubMed&url=http://www.fda.gov/fdac/departs/2006/106_upd.html#hormone

HSL5422
Montori VM, Leung TW, Devereaux PJ, Schunemann HJ, Akl EA, Gafni A, Guyatt GH.
Can contraindications compromise evidence-based, patient-centered clinical practice?
Can J Clin Pharmacol 2006 Win;13(1):e92-101

HSL5081
Harris PR, Napper L.
Self-affirmation and the biased processing of threatening health-risk information.
Pers Soc Psychol Bull 2005 Sep;31(9):1250-63
http://psp.sagepub.com/cgi/reprint/31/9/1250

HSL5852
Bates DW.
Computerized physician order entry and medication errors: finding a balance.
J Biomed Inform 2005 Aug;38(4):259-61
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WHD-4G9PW3B-1&_coverDate=08%2F31%2F2005&_alid=418671447&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=6848&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=28f7a2652056bab5942c02906fc4246f

HSL5300
Damodaran RT.
Brand confusion causes allergic dermatitis.
J Postgrad Med 2005 Jul-Sep;51(3):242
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3153&uid=16333208&db=PubMed&url=http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2005;volume=51;issue=3;spage=242;epage=242;aulast=Damodaran

HSL1912
Harris G, Koli E.
Lucrative Drug, Danger Signals and the F.D.A.
2005 Jun 10

HSL1909
Berenson A.
At Pfizer, the Isolation Increases for a Whistle-Blower: No man is an island. But Peter Rost is getting close.
2005 Jun 8

HSL1908
Don't use growth hormone sold over web: Health Canada
CBC News 2005 Jun 7

HSL1905
Levin M.
Firm Removed Mercury From Nasal Spray, Not Infant Shots: Wyeth used thimerosal in vaccines for years after it did away with the chemical in Dristan.
The LA Times 2005 Jun 4

HSL5892
Nebeker JR, Hoffman JM, Weir CR, Bennett CL, Hurdle JF.
High rates of adverse drug events in a highly computerized hospital.
Arch Intern Med 2005 May 23;165(10):1111-6
http://archinte.ama-assn.org/cgi/content/full/165/10/1111

HSL1871
Solomon J.
Government tested AIDS drugs on foster kids: Children not provided with basic legal protection, review finds
The Associated Press 2005 May 4

HSL4219
Hamrin V, Scahill L.
Selective serotonin reuptake inhibitors for children and adolescents with major depression: current controversies and recommendations.
Issues Ment Health Nurs 2005 May 01;26(4):433-50

HSL4233
Allen TS Jr, Henderson JH Jr.
Merck VIOXX "warning" is questioned.
Tex Med 2005 May 01;101(5):5-6

HSL2483
Mebane FE.
The importance of news media in pharmaceutical risk communication: proceedings of a workshop.
Pharmacoepidemiol Drug Saf 2005 May;14(5):297-306
http://www3.interscience.wiley.com/cgi-bin/abstract/109596257/ABSTRACT

HSL1773
Morgan D, Kaufman M.
FDA Calls Efforts For Bayer Illegal: Lawmakers' Help for Drug Firm Tests Limits
The Washington Post 2005 Apr 30

HSL1842
Friedman R.
Mix Math and Medicine and Create Confusion
The New York Times 2005 Apr 26

HSL5885
Koppel R, Metlay JP, Cohen A, Abaluck B, Localio AR, Kimmel SE, Strom BL.
Role of computerized physician order entry systems in facilitating medication errors.
JAMA 2005 Mar 9;293(10):1197-203
http://jama.ama-assn.org/cgi/content/full/293/10/1197

HSL5925
Wears RL, Berg M.
Computer technology and clinical work: still waiting for Godot.
JAMA 2005 Mar 9;293(10):1261-3
http://jama.ama-assn.org/cgi/content/full/293/10/1261

HSL4049
'Black box' warning added to contraceptive injection.
FDA Consum 2005 Mar-Apr 01;39(2):3
http://www.fda.gov/fdac/departs/2005/205_upd.html

HSL4050
New warning about ADHD drug.
FDA Consum 2005 Mar-Apr 01;39(2):3
http://www.fda.gov/fdac/departs/2005/205_upd.html

HSL2654
De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG.
Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.
Eur Heart J 2005 Mar;26(6):590-7
http://eurheartj.oxfordjournals.org/cgi/content/full/26/6/590

HSL5087
Torg J.
Vioxx and Merck: a preventable situation?
Orthopedics 2005 Mar;28(3):248,

HSL6128
Herxheimer A.
Communicating with Patients about Harms and Risks
PLoS Med 2005 Feb 22;2(2)
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020042

HSL4171
Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
Lancet 2005 Feb 5-11;365(9458):475-81
http://linkinghub.elsevier.com/retrieve/pii/S0140673605178647

HSL5244
Halpern GM.
COX-2 inhibitors: a story of greed, deception and death.
Inflammopharmacology 2005;13(4):419-25
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3152&uid=16354394&db=PubMed&url=http://openurl.ingenta.com/content/nlm?genre=article&issn=0925-4692&volume=13&issue=4&spage=419&aulast=Halpern

HSL5965
Jureidini JN, Tonkin A.
Suicide and antidepressants in children (editorial)
Australian Prescriber 2005;28:110-1
http://www.australianprescriber.com/magazine/28/5/110/1/

HSL2210
Huh J, Cude BJ.
Is the information "fair and balanced" in direct-to-consumer prescription drug websites?
J Health Commun 2004 Nov-Dec;9(6):529-40
http://journalsonline.tandf.co.uk/app/home/contribution.asp?wasp=97293d9777854ef4b987a516126c380c&referrer=parent&backto=issue,4,9;journal,5,49;linkingpublicationresults,1:100673,1

HSL5966
Fitzgerald GA.
Coxibs and cardiovascular disease.
N Engl J Med 2004 Oct 21;351(17):1709-11
http://content.nejm.org/cgi/content/extract/351/17/1709

HSL2819
Romero CE, Baron JD, Knox AP, Hinchey JA, Ropper AH.
Barbiturate withdrawal following Internet purchase of Fioricet.
Arch Neurol 2004 Jul;61(7):1111-2
http://archneur.ama-assn.org/cgi/content/full/61/7/1111

HSL5860
Berger RG, Kichak JP.
Computerized physician order entry: helpful or harmful?
J Am Med Inform Assoc 2004 Mar-Apr 01;11(2):100-3
http://www.jamia.org/cgi/content/full/11/2/100

HSL2794
Jorgensen KJ, Gotzsche PC.
Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study.
BMJ 2004 Jan 17;328(7432):148
http://bmj.bmjjournals.com/cgi/content/full/328/7432/148

HSL5212
Gulhati CM.
Needed: closer scrutiny of clinical trials.
Indian J Med Ethics 2004 Jan-Mar;1(1):4-5

HSL2783
Hall TS.
Reimagining the learned intermediary rule for the new pharmaceutical marketplace.
Seton Hall Law Rev 2004;35(1):193-261

HSL5438
Kabra SG.
Unsafe abortions and experimental excesses.
Issues Med Ethics 2003 Jul-Sep 01;11(3):79-80

HSL5882
Kaushal R, Shojania KG, Bates DW.
Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review.
Arch Intern Med 2003 Jun 23;163(12):1409-16
http://archinte.ama-assn.org/cgi/content/full/163/12/1409

HSL2676
Lehner JP, Meyer F, Juillet Y.
[Communication and transparency concerning risk-benefit analysis in public health: the example of medication]
Therapie. 2001 Jul-Aug;56(4):335-9 2002 Jul-Aug 01;56(4):335-9

HSL2859
Hoye S, Hjortdahl P.
New wonder pill!--what do Norwegian newspapers write
2002 Jun 30;122(17):1671-6 2002 June 30;122(17):1671-6
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12555610

HSL2861
Hoogenberg K, van der Tuin J.
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Ned Tijdschr Geneeskd. 2002 November 2;146(44):2099-100
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12448967

HSL6147
Shann F.
Uses of error: the wrong research costs lives.
Lancet 2001 May 26;357(9269):1691
http://linkinghub.elsevier.com/retrieve/pii/S0140673600048790

HSL5855
Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, Boyle D, Leape L.
The impact of computerized physician order entry on medication error prevention.
J Am Med Inform Assoc 1999 Jul-Aug 01;6(4):313-21
http://www.jamia.org/cgi/content/full/6/4/313

HSL5854
Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, Burdick E, Hickey M, Kleefield S, Shea B, Vander Vliet M, Seger DL.
Effect of computerized physician order entry and a team intervention on prevention of serious medication errors.
JAMA 1998 Oct 21;280(15):1311-6
http://jama.ama-assn.org/cgi/content/full/280/15/1311

HSL711
Judge R.
Dangers of fluoxetine.
Lancet 1997 Mar 15;349(9054):809

HSL736
Bourguignon RP.
Dangers of fluoxetine.
Lancet 1997 Jan 18;349(9046):214

HSL856
Cooper RS.
Risks and benefits of calcium antagonists.
Lancet 1995 Oct 7;346(8980):961

HSL5853
Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, et al.
Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group.
JAMA 1995 Jul 5;274(1):29-34

HSL3134
Kline S.
Prescription drug advertising: Communicating risk, benefit and cost of pharmaceuticals
Canadian Public Health Association 1992 Feb 2-4:52-6

HSL4936
Wivell MK, O’fallon DA.
Drug overpromotion: when is a warning not a warning?
Trial 1992;28(11):20-27

HSL4686
Moser M, Blaufox MD, Freis E, Gifford RW Jr, Kirkendall W, Langford H, Shapiro A, Sheps S.
Who really determines your patients' prescriptions?
JAMA 1991 Jan 23-30;265(4):498-500
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1985236&query_hl=45

HSL3131
Lee PR, Lurie P, Silverman MM, Lydecker M.
Drug promotion and labeling in developing countries: an update.
J Clin Epidemiol 1991;44

HSL4664
Herxheimer A, Lundborg CS, Westerholm B.
Advertisements for medicines in medical journals: a collaborative international study
1991

HSL4125
Beasley R, Crane J, Burgess C, Pearce N, Jackson R.
Fenoterol and severe asthma mortality
New Zealand Medical Journal 1989;102:294-295

HSL4004
Hemminki E.
Commercial information on drugs: confusing the physician?
Journal of Drug Issues 1988;18:245-257

HSL2722
Soumerai SB, Avorn J, Gortmaker S, Hawley S.
Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene.
Am J Public Health 1987 Dec;77(12):1518-23
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3674250&query_hl=59

HSL3936
Double standards—some improvements
HAI News 1987 Feb(33):1-2, 12

HSL3937
MLAM letter follow up—Pfizer
1987 Feb:2

HSL3935
Hoechst a cause of illness? The pharmabusiness in the Third World
1987 Jan

HSL3930
Wolffers I.
Drug information and sale practices in some pharmacies of Colombo, Sri Lanka.
Soc Sci Med 1987;25(3):319-21

HSL3976
Tucker GK, Smith MC.
Direct-to-consumer advertising: Effects of different formats of warning information disclosure on cognitive reactions of adults
Journal of Pharmaceutical Marketing & Management 1987;2(1):27-41

HSL3846
Re: the promotion of amrinone
1986 Sep

HSL3837
Re: the promotion of Rheopyrine
1986 Apr

HSL1041
Mansfield P.
Phenylbutazone.
Med J Aust 1986 Jan 6;144(1):55

HSL3821
Silverman M, Lee PR, Lydecker M.
Drug promotion: the Third World revisited.
Int J Health Serv 1986;16(4):659-67

HSL3749
Morris LA, Ruffner M, Klimberg , R .
Warning disclosures for prescription drugs
Journal of Advertising Research 1985 Oct-Nov;25(2):25-32

HSL1042
Mansfield P.
Phenylbutazone.
Med J Aust 1985 Sep 2;143(5):219-20

HSL3681
Re: the promotion of ethylestrenol
1984 Jul 01

HSL3677
Re: the promotion of Lomotil
1984 May 01

HSL3673
Re: the promotion of dipyrone
1984 Apr 01

HSL3655
Schapiro R.
Rx: consumer ads. Promoting prescription drugs to the consumer
New Physician 1984;33(4):8-11

HSL3576
Brooks PM, Birkett D.
Release of new drugs. The lessons of benoxaprofen
Med J Aust. 1983 Mar 19;1(6):251-2

HSL3568
'Opren scandal'
Lancet 1983 Jan 29;1(8318):219-20 1983 Jan 29;1(8318):219-20

HSL3591
Osifo NG.
Overpromotion of drugs in international product package inserts.
Trop Doct 1983 Jan;13(1):5-8

HSL3554
Silverman M, Lee PR, Lydecker M.
Prescriptions for death: the drugging of the Third World
Berkeley: University of California Press; 1982

HSL3530
Freese B, Medawar C, Herxheimer A.
No more lomotil for infants.
Lancet 1981 Oct 10;2(8250):816-7

HSL3305
Hendeles L.
Need for "counter-detailing" antibiotics.
Am J Hosp Pharm 1976 Sep;33(9):918-24

HSL3329
Hodes B.
Are magazine ads for O-T-C drugs based on fact?
J Am Pharm Assoc 1976 Sep;16(9):513-5

HSL3300
Dunne M, Flood M, Herxheimer A.
Clioquinol: availability and instructions for use
Journal of Antimicrobial Chemotherapy 1976;2:21-29

HSL3283
Erill S, Souich PD, Garcia-Sevilla JA.
Chloramphenicol-containing drugs. A report from Spain
J Clin Pharmacol . 1975;15:401-404
http://jcp.sagepub.com/cgi/reprint/15/5/401

HSL3250
Schreier HA, Berger L.
Letter: On medical imperialism.
Lancet 1974 Jun 8;1(7867):1161

HSL3256
Greenberg D.
Cleaning up the drug trade
New Scientist 1974 May 23;62:491

HSL3232
Dunne M, Newman M, Herxheimer A, Ridley H.
Indications and warnings about chloramphenicol.
Lancet 1973 Oct 6;2(7832):781-3